Online inquiry

IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13328MR)

This product GTTS-WQ13328MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13328MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10285MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ9228MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ15222MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ2241MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ15001MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ11297MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ11617MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ10686MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW